In This Section

Epigenetics in Drug Discovery

Sunday April 22, 2018

3:30 pm - 6:00 pm Eastern Time (ET)

Room 15B


Chair :

Joseph Jilek
University of California, Davis

Venkat Vaka
University of Mississippi Medical Center

Epigenetics is defined as the study on heritable changes in gene expression without any alterations in primary DNA sequence. Alterations in epigenetic control mechanisms lead to aberrant gene expression patterns and contribute to the pathogenesis of various diseases, including cancer, cardiovascular, and neurodegenerative diseases.The proposed symposium will introduce the topic of epigenetics and its pivotal role in drug discovery. Symposium will highlight recent advances in epigenetics research and the opportunities in leveraging epigenetic mechanisms to target-based discovery and development. Progress made in the application of the field to the development of potential therapeutics to areas beyond cancer will be discussed.


Patrick Woster - Medical University of South Carolina College of Pharmacy

Epigenetic Drug Discovery Beyond Cancer

Sharad Verma - Johns Hopkins School of Medicine

Therapy Acceleration via Precision Medicine

Ai-Ming Yu - University of California, Davis

MicroRNA Epigenetics & Therapy: Are We Using the Right Agents?

Nate Hathaway - UNC Eshelman School of Pharmacy

Pathway Based Chemical Screen Identifies New Components of Epigenetic Gene Repression as Potential New Cancer Therapeutics

Seena Ajit - Drexel University College of Medicine

Exosome Mediated Intercellular Communication in Pain

Gwen Lomberk - Medical College of Wisconsin

Targeting of the Histone 3 Lysine 9 Methyltransferase Pathway in Kras-Induced Cell Growth and Pancreatic Cancer

Jia Cui - University of Alabama-Birmingham

Crosstalk Between PTBP1 and miR-101/AGO2 on Targeting MCL1  – A Novel Post-Transcriptional Mechanism for MCL1 Expression